Boehringer Ingelheim has joined the consortium, effective since July 2017

The Boehringer Ingelheim (BI) pharmaceutical company made a formal proposal to join the TransQST consortium in June 2017. The TransQST partners found their addition to be an excellent opportunity to complement and extend the coverage of the modeling framework within the particular area of GI toxicity assessment (WP8).

SYNAPSE has coordinated the documentation preparation between BI and the IMI officer to fulfil the IMI requirements for the onboarding of a new partner. Since 1st of July 2017 as the effective starting date, BI has become the 22nd partner of the TransQST consortium, with a contribution of 1,5 M €.